Ratio parameters of bulk drugs

849. PROF. B. RAMACHANDRA RAO:
PROF. (MRS.) ASIMA CHATTERJEE:

Will the Minister of INDUSTRY be pleased to state:

(a) what are the ratio parameters of Bulk drug to Formulation Production-fixed by the Government for the Indian and FERA and Ex-FERA Companies;

(b) what was the actual position during 1976-77 and 1982-83;

(c) if the actual figures are different from those stipulated what are the reasons thereof; and

(d) the action proposed to be taken by Government to rectify this imbalance?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) According to 1978 Drug Policy a FERA company will be granted fresh industrial licence for formulations, *inter-alia*, only ig the ratio of bulk drug consumption to that of formulations is 1:5. Similarly, other companies will be allowed formulation licences upto 10 times of the value of their bulk drug production.

(b) The concept of ratio parameters were not in existence during 1976-77. All companies in the organised sector fulfilled the conditions of ratio parameters during 1982-83 except 14 companies listed below:

1. M/s. Abbott Labs. (I) Pvt. Ltd.
2. M/s. Chowgule & Co. (Hind) Pvt. Ltd.,
3. M/s. Deys' Medical Stores (Mfg.) Ltd.,
4. M/s. Amrutanjan Limited
4. M/s. J. L. Morison & Jones (I) Ltd.,
6. M/s. Orient Pharma (P) Ltd..
7. M/s. Dabur Limited
8. M/s. Smith, Kline & French
9. M/s. Roussel Pharmaceutical Limited
10. M/s. Warner Hindustan Limited
11. M/s. Anglo French
12. M/s. E. Merck (I) Limited
13. M/s. Sandoz (I) Limited
14. M/s. Tamilnadu Dhadha Pharmaceuticals Limited

(c) and (d) None of the above companies have been granted fresh licences for additional formulations in relaxation of the drug policy parameters. It may also be mentioned that since 1982-83 M/s. Sandoz (I) Limited, M/s. E. Merck and M/s. Tamilnadu Dhada Pharmaceuticals have increased their bulk drug production and they now conform to the ratio parameter. M/s. Abbott Labs. and M/s. Roussel Pharmaceuticals Limited have since reported production of bulk drugs.

Updating technologies of certain drugs by IDPL

850. SHRI MAHENDRA MOHAN MISHRA: Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention has been drawn to the news which appeared in 'Financial Express' dated the 29th January, 1986 under the heading 'IDPL may turn corner by next year';

(b) if so, whether it is a fact that IDPL has decided to update the technologies of certain drugs where production is not economical;

(c) whether it is a fact that those drugs are being produced by other drug companies in the country with indigenously developed technologies and found the process very successful;

(d) if so, names of those companies alongwith the name of each drug and production during the last three years, year-wise;

(e) whether IDPL will approach foreign companies for updating the technologies or will seek the help from CSIR laboratories; and

(f) what are the details of plans of IDPL?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) Yes, Sir.

(c) and (d) Of the 9 drugs identified by IDPL for upgradation of Technology, two, namely Griseofulvin and Vitamin B6 are not produced by any other company in the country. The other bulk drugs whose technology is sought to be upgraded and which are being produced in the country are Pot. Penicillin, Erythomycin, Tetracycline, Oxytetracycline, Streptomycin, Doxy-cycline and Chloroquin Phosphate. Production details, to the extent readily available, in the last three years, are given in the Annexure.

(e) and (f) IDPL is making efforts for obtaining technology of Griseofulvin from outside. Technology for Pot. Penicillin is being updated with the help of HAL. For other drugs, IDPL is planning to update the technology at its own R&D units.

Annexure

Name of the Drug/Company	A/C unit	Production		
		1982-83	1983-84	1984-85
1	2	3	4	5
1. *Erythromycin*				
(i) IDPL		..	1·10	..
(ii) Themis Pharma		15·42	12·66	10·11
(iii) Alembic Chem		14·70	17·75	9·00
	TOTAL :	30·12	31·51	19·11
2. *Tetracycline*				
(i) IDPL		129·89	115·20	121·30
(ii) Cynamid		8·91	2·19	11·10
(iii) Synbiotics		70·34	91·15	94·64
	TOTAL :	209·14	208·54	227·04
3. *Oxytetracycline*				
(i) IDPL		49·72	20·50	49·20
(ii) Pfizer		69·85	84·49	86·40
	TOTAL :	119·57	104·99	135·60

1	2	3	4	5
4. *Streptamycin*	T			
(i) IDPL		40·19	35 80	27·10
(ii) HAL		120·11	111·79	111·68
(iii) Synbiotics		79·30	90·72	96·28
TOTAL :		239·60	238·31	235·06
5. *Doxycycline*	T			
(i) IDPL		0·01	..	..
(ii) Ranbaxy		0·68	1·66	4·32
TOTAL :		0·69	1·66	4·32
6. *Chloroquin Phos*	T			
(i) IDPL		..	..	0·25
(ii) BIL		2·43	3·11	3·65
(iii) B.E.C. Chem		9·16	23·33	22·01
(iv) Suneeta Lab.		12·79	25·57	34·84
(v) Ranbaxy Lab.		21·78	35·78	51·16
(vi) Bayer (I)		33·51	34·79	35·48
TOTAL :		79·67	122·58	147·39
7. *Pot. Penicillin (Gress)*	MMU			
(i) IDPL		92·70	123 00	129·50

Increase in the price of cellubril capsules etc.

851. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that during the last four to five years Drug Companies have increased the prices of day-to day required medicines of Cellubril Capsules Cremaffin Liquid, Dulcolax Tablets, Surpositories, Evaclnol Granules, Glaxenna Tablets, Ka. normal Predniflex Tablets, Parafon Tablets Neooctinum dragees, drops, injections, Doudil Tablets Carisoma Compound Tablets, Aminozyme Liquid Bilamide Tablets. Dispeptal dragees, Dispeptase Liquid, Lupizyme Liquid, Merckenzyme Tablets, Merizyme Tablets, Liquid, Molzyme Tablets, Panzynorm Tablets Ralcrizyme dragees and Unienzyme Tablets, Agarol Liquid, Sanzyme Tablets between 75 per cent to 209 per cent; and

(b) if so, what was the price of each pack at the time of announcement of Drugs Price Control Order, 1979 and what is the present price alongwith the percentage increase of price in each product?